RETINOBLASTOMA

share
Last Updated : 1/3/2011
Font-size :  
Bharat R Agarwal
More..
Apart from loss of vision and systemic spread of the disease, it has been found that 5% to 15% of children with either familial, multifocal or bilateral Retinoblastoma may develop an intracranial neuroblastic tumor (pinealoma). Also, patients with germline type of tumor may have increased risk of second malignant neoplasms e.g. osteosarcomas, soft tissue sarcomas & melanomas. Children with germline tumor may develop bilateral disease even if only one eye is involved at presentation. Hence, they should be examined frequently for the development of new Retinoblastoma tumors. It has been recommended that they should be examined every 2 to 4 months for at least 28 months and following treatment followed up until 7 years of age.

Relapse
If the relapse is confined to the eye and tumor is small, it can be treated with local therapy alone. The prognosis for vision and survival is excellent.

If relapse is confined to the eye, but is extensive, treatment with etoposide & carboplatin can be tired. The prognosis for vision is poor but survival remains excellent. If relapse is extraocular, the prognosis is less than 50%.



Contributor Information and Disclosures Bharat R Agarwal
Pediatric Hematologist- Oncologist, Division of Pediatric Hem-Onco, B.J. Wadia Hospital for Children, Mumbai, India


First Created : 1/3/2001
References
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.